Biocon Launches ₹4,500 Crore QIP to Strengthen Balance Sheet and Reduce Debt
Key Insights
Biocon launched a ₹4,500 crore Qualified Institutional Placement with a floor price of ₹340.20 per share to strengthen its financial position.
The net proceeds will be used to purchase outstanding optionally convertible debentures from Goldman Sachs (search) and repay existing borrowings.
The capital raise aims to pare down debt and bolster the Bengaluru-based biopharmaceutical company's balance sheet.
Biocon launched its Qualified Institutional Placement (QIP) issue on Monday to raise ₹4,500 crore, setting the floor price at ₹340.20 per share according to SEBI pricing regulations. The biopharmaceutical company may offer up to a 5% discount on this floor price while finalizing the issue price in consultation with book-running lead managers.
QIP Structure and Pricing
According to sources, the indicative price for the block deal is ₹323.20 per share, reflecting a discount of up to 9.53% to the current market price. The company's shares closed 0.44% higher at ₹356.95 on the NSE ahead of the announcement. Trading in Biocon securities remains restricted due to the insider trading code in place during the issue.
Use of Proceeds
The net proceeds from the QIP will serve multiple strategic purposes. The primary use will be to purchase outstanding optionally convertible debentures issued by its subsidiary Biocon Biologics (search) from Goldman Sachs (search)' AIF schemes. Additionally, the funds will help in repaying or prepaying existing borrowings, redeeming financial instruments, and meeting other financial commitments.
Regulatory Approvals and Timeline
The issue received board approval in April and obtained shareholder approval through a postal ballot on June 4. The board has also sanctioned an increase in authorized share capital from ₹625 crore to ₹700 crore, which requires both shareholder and regulatory approval through a postal ballot process.
Strategic Rationale
The capital raise is aimed at paring down debt and bolstering the Bengaluru-based company's balance sheet. Kotak Mahindra Capital (search), Goldman Sachs (search) (India), and BofA Securities India (search) are advising Biocon on the capital raise.
Company Profile
Headquartered in Bengaluru, Biocon is a biopharmaceutical major involved in the production of generic active pharmaceutical ingredients (APIs) and biosimilars. The firm operates in both domestic and overseas markets with a focus on affordable healthcare and product development through innovation.